Xencor (XNCR) Profit After Tax (2013 - 2026)
Xencor (XNCR) reported Profit After Tax of -$128.9 million for Q1 2026, down 165.08% year-over-year from $198.1 million in Q1 2025, and down 1902.11% quarter-over-quarter from -$6.4 million in Q4 2025.
Xencor (XNCR) Profit After Tax (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Profit After Tax data on file, last reported at -$128.9 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$128.9 million, down 165.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$172.2 million (up 17.96% YoY), and the FY2025 annual result was -$91.9 million, up 61.14% from the prior year.
- Profit After Tax declined to -$128.9 million in Q1 2026 per XNCR's latest filing, from -$6.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at $23.6 million in Q1 2022 and troughed at -$128.9 million in Q1 2026.
- A 5-year average of -$37.9 million and a median of -$32.8 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax soared 1048.69% in 2022, then tumbled 357.54% in 2023.
- A 5-year view of Profit After Tax shows it stood at -$12.0 million in 2022, then plunged by 117.13% to -$26.1 million in 2023, then sank by 76.69% to -$46.2 million in 2024, then soared by 86.06% to -$6.4 million in 2025, then sank by 1902.11% to -$128.9 million in 2026.
- Business Quant data shows XNCR's Profit After Tax at -$128.9 million in Q1 2026, -$6.4 million in Q4 2025, and -$6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | -128.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128.92 Mn |
| Dec 31, 2025 | -6.44 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.83 Mn |
| Mar 31, 2025 | -48.63 Mn |
| Dec 31, 2024 | -46.20 Mn |
| Sep 30, 2024 | -46.29 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.15 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -21.95 Mn |
| Mar 31, 2023 | -60.76 Mn |
| Dec 31, 2022 | -12.04 Mn |
| Sep 30, 2022 | -32.76 Mn |
| Jun 30, 2022 | -33.98 Mn |
| Mar 31, 2022 | 23.59 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.19 Mn |
| Jun 30, 2021 | 52.25 Mn |